Aktiesnakken — Februar 2010
-
nævn nu arzerra din hat
-
han nævner alle mulige produkter - nu arzerra
-
biopharm is moving forward....
-
19% af RD er i Biopharm
-
ok det var så det
-
we are not getting drawn into m&a
-
det lød som om genmab har budt sig til
-
men fået nej
-
ikke genmab specifik....men han er ikke nice rich uncle
-
nu noget om ændring i investering i R&D
-
best science, diversify, greater externalisation
-
highest number of approval in fda
-
i de sidste 3 år
-
stinker har du linket til slides?
-
-
man skifter bare tallet
-
grow biopham pipeline - lækkert
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind